
1. CEAT:
Thistyre manufacturersurged over 10% on Monday following the acquisitionannouncement of Camso's Off-Highway tyres (OHT) business from Michelin in an all-cash deal, valued at approximately $225 million (Rs 1,909 crore).
The acquisition of Camso is expected to strengthen CEAT's position in the OHT market, which currently contributes around 15% of revenues, and widen its customer base. The acquisition also provides CEAT with access to a global network of over 40 international OEMs and premium OHT distributors.
InQ2 FY25, the company’s revenue increased 8% YoY, but net profit declined by 41.4% on a YoY basis. Even though revenue was in line with Forecasterestimates, net profit missed estimates by 16.4%, due to higher raw material prices in rubber and crude. However, based on Trendlyne’sindustry dashboard, Ceat has outperformed other major players in the auto tyres space over the past month and quarter.
Gross margins declined by 194 bps on a QoQ basis and by 587 bps on a YoY basis in Q2. MD & CEO, Arnab Banerjee,said, “The raw material prices escalated at a very steep rate of 6% (in) Q2 over Q1. It's very difficult to pass on the entire increase through finished goods in such a short period.” CEAT took price hikes across the board in September, and management hints at a further 1.5-2% hike for passenger, truck, and bus tyres.
Given that Camso is a tier-one brand, CFO Kumar Subbiah expects this acquisition to be margin accretive. Camso's off-highway construction equipment tyre and tracks business clocked revenue of around $200 million in 2023 and at the same run rate, Ceat’s revenue from the off-highway tyre business should double once the merger is complete.
2. Zen Technologies:
This defence company has risen by 14.9% in the past week after it made a push into the US defence market. Zen Technologies announced a partnership with Applied Visual Technology (AVT) Simulation, a provider of customized training systems, in Florida. The collaboration should boost simulation and training solutions for defence and security forces.
The company received an Indian patent on November 26 for its tank simulator, the T90 Containerized Crew Gunnery Simulator (T90 CGS). This system enables instructors to customize training scenarios, from basic skill tests to more complex exercises that involve the entire crew working together.
Chairman and MD Ashok Atluri said, "We expect a sizable revenue from this new technology, potentially contributing 5-10% of our revenues over the next three years." He added that the company has demonstrated the product to the US government, though it may take a couple of years before any deals materialize. However, the company expects opportunities in other countries to come sooner. Speaking about the market size, Atluri said, "Our estimates indicate that the market for tank simulators in India is around Rs 4,000 crore and nearly $1 billion overseas."
In Q2FY25, the company’s net profit surged 4.1X YoY to Rs 62.7 crore, while operating revenue grew 3.6X YoY to Rs 241.8 crore, surpassing Trendlyne Forecaster estimates by 26.7% and 20.8%, respectively. As of Q2, the company had an order backlog of ~Rs 960 crore, with an order pipeline of Rs 3,500 crore. The management expects to receive Rs 1,200 crore in orders during H2FY25.
Motilal Oswal retains its ‘Buy’ call on Zen Technologies with a target price of Rs 2,400. This indicates a potential upside of 10.7%. The brokerage is positive about Zen's partnership with AVT Simulation. It anticipates 67% and 65% CAGR in revenue and net profit over FY25-27, driven by increased order inflows and better working capital management.
3. Bajaj Finance:
This NBFC company has risen 4.8% in the past week, following its investor day on December 10. During the event, Bajaj Finance outlined its long-term strategy and its plans to transition into a FinAI company.
Under its 2025-29 long-range strategy (LRS), Bajaj Finance aims to grow its customer base to approximately 20 crore and double its retail credit market share to 4-5%. This is a big jump from the company’s current customer base, which stood at 9.2 crore in H1FY25. It also plans to enhance its market presence and increase from 4,245 locations so far in FY25 to over 5,200 by FY29.
The NBFC also unveiled plans to evolve into BFL 3.0, a FinAI company – powered by fintech and AI, over the next 4-5 years. Bajaj Finance will deploy AI across all its processes, which will help improve efficiency, reduce costs, and enhance customer engagement. Commenting on this, Manish Jain, the CEO said, “We are currently implementing 29 GenAI use cases across 25 workstreams, which is expected to drive cost savings of around Rs 150 crore annually in FY26. You will see this adoption accelerating rapidly in the coming months”.
In addition, the company highlighted three megatrends in focus - Green Finance, Multi Cloud, and Zero Trust. Bajaj Finance will extend financing for solar and EV products to retail and MSME customers, starting Q4FY25, and targets Rs 2,000 crore of green finance by FY26.
Bajaj Finance’s net profit had surged 80.8% YoY to Rs 5,613.7 crore in Q2FY25. Revenue increased 27% to Rs 14,491.8 crore, driven by higher assets under management (AUM). The company’s AUM reached Rs 2.8 lakh crore in Q2, a rise of 28% YoY. Bajaj Finance projects an AUM of Rs 4 lakh crore for FY25, and analysts believe it is well-positioned to achieve the target.
Anand Rathi maintains its ‘Buy’ rating on Bajaj Finance with a target price of Rs 7,905. The brokerage believes the company is well poised to achieve its long-range targets due to its strong execution skills, robust customer base, and strong tech architecture.
4. Metropolis Healthcare:
Thishealthcare services company rose 2.6% on December 9 after its board approved theacquisition of a 100% stake in Delhi NCR headquartered Core Diagnostics, for Rs 246.8 crore. Core Diagnostics specialises in oncology testing, offering 1,300 tests and serving more than 6,000 specialty prescribers.
The managementbelieves the acquisition will strengthen the company’s specialty portfolio, including therapy monitoring and cancer confirmatory tests, enhancing its presence in the Rs 4,000-5,000 crore oncology diagnostics market, which is expected to grow at a CAGR of 17.5% from FY25-28. With this acquisition, Metropolis’ revenue contribution from oncology isexpected to grow to 10% from 4%, while specialty contribution will inch up to 41% from 37%. Core Diagnostics’ average revenue per test (ARPT) is Rs 2,300 which is 4.5 times than that of Metropolis Healthcare.
Surendran Chemmenkotil, CEO of Metropolis Healthcaresaid, "With the majority of Core’s revenue coming from Northern and Eastern India, this acquisition provides an opportunity to connect with leading hospitals in these regions." After the merger, Metropolis’ oncology sales team is set toincrease by 3.6 times to 130.
InQ2FY25, Metropolis Healthcare reported a net profit growth of 31.2% YoY to Rs 46.5 crore. Revenue increased 14% YoY to Rs 352.9 crore during the quarter, driven by a 7% growth in number of patients to 3.4 million and a 6% rise in revenue per patient to Rs 1,025. Commenting on the results, Chemmenkotilsaid, “We aim to achieve double-digit volume growth by focusing on our B2C segment and specialty tests while expanding our network to 1,000 towns in the next 12 to 18 months.”
Post the announcement of the acquisition, ICICI Securitiesmaintained its ‘ADD’ rating on Metropolis Healthcare with a target price of Rs 2,335. The brokerage expects an earnings CAGR of 32% over FY25-27 with revenue CAGR at 18.6%. It also expects EBITDA margin to remain in the range of 26-28% over FY26-27.
5. Kalpataru Projects International:
This construction & engineering company has risen by over 4% in the past week. On December 9th, the company and some of its international subsidiaries, secured new orders worth Rs 2,174 crore. These include an elevated metro rail project and a residential building project in India, along with orders in the Transmission & Distribution (T&D) sector both domestically and internationally. Speaking on the newly received orders, the company’s MD & CEO, Manish Mohnot, said, “With these orders, our YTD order inflow stands over Rs 16,300 crore, more importantly; nearly 85% of order intake till date is from our T&D and building & factories (B&F) business.”
KPIL posted a 41% YoY rise in net profit to Rs 125.5 crore in Q2FY25, and a 9.2% YoY increase in revenue due to segment wise revenue jumps in Urban Infra and T&D. The company however missed the Trendlyne Forecaster estimates for revenue by 1% and the net profit estimate by 9.7% due to weaknesses in railways and water segments on the back of delay in tendering and execution activities. It appears in a screener of stocks which have high momentum scores.
The company’s order book as of Q2FY25 stands at Rs 60,631 crore, out of which its T&D business and B&F business contributes the most at 37% and 22%, respectively. Sharekhan analysts estimate that India’s total capital expenditure in infrastructure sectors till FY25 will be around Rs 111 lakh crore. This substantial investment in infrastructure is expected to create strong growth opportunities for the company.
Manish Mohnot, CEO & managing director of the company, said, “Margins are improving due to the new, higher-margin order book secured over the last two years, with positive impact expected for the next 6-8 quarters. We foresee growth and margin improvement over the next two years and are confident in meeting our commitments. Despite challenges in the water business, mainly related to collections in some states, we remain focused on long-term growth.”
Sharekhan has maintained its ‘Buy’ rating on KPIL with a revised target price of Rs 1,570. The brokerage notes that the company’s Q2FY25 standalone performance was slightly weak on margins and profitability, though sales met expectations. It expects improvement driven by a strong order book, better JV & subsidiary performance, and reduced promoter pledges, all of which could act as key re-rating catalysts.
Trendlyne's analysts identify stocks that are seeing interesting price movements, analyst calls, or new developments. These are not buy recommendations.